DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
299	嚢胞性線維症	3

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00794586 (ClinicalTrials.gov)	November 2008	18/11/2008	Study Evaluating Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients With Pseudomonas Aeruginosa Lung Infection	A Phase 2, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Fosfomycin/Tobramycin for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa	Cystic Fibrosis	Drug: FTI, AZLI;Drug: Placebo, AZLI	Gilead Sciences	NULL	Completed	18 Years	N/A	Both	120	Phase 2	United States
2	NCT01400750 (ClinicalTrials.gov)	August 2001	18/7/2011	Comparison of 2 Treatment Regimens for Eradication of P Aeruginosa Infection in Children With Cystic Fibrosis	Prospective Randomized Trial Comparing Oral Ciproxin Plus Inhaled Colistin With Tobramycin for Inhalation for Eradication of P Aeruginosa Infection in Children With Cystic Fibrosis.	Cystic Fibrosis	Drug: oral ciprofloxacin plus inhaled colistin;Drug: TOBI	Universitaire Ziekenhuizen Leuven	NULL	Completed	N/A	18 Years	Both	61	Phase 4	Belgium
3	NCT00006280 (ClinicalTrials.gov)	February 2000	11/9/2000	A Study of the Safety and Efficacy of Tobramycin for Inhalation in Young Children With Cystic Fibrosis	A Phase II Multicenter Randomized Trial of Tobramycin for Inhalation in Young Children With Cystic Fibrosis	Cystic Fibrosis	Drug: Tobramycin for Inhalation	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	National Center for Research Resources (NCRR)	Completed	6 Months	5 Years	Both	98	Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00794586
(ClinicalTrials.gov)

November 2008

18/11/2008

Study Evaluating Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients With Pseudomonas Aeruginosa Lung Infection

A Phase 2, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Fosfomycin/Tobramycin for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa

Cystic Fibrosis

Drug: FTI, AZLI;Drug: Placebo, AZLI

Gilead Sciences

NULL

Completed

18 Years

N/A

Both

120

Phase 2

United States

NCT01400750
(ClinicalTrials.gov)

August 2001

18/7/2011

Comparison of 2 Treatment Regimens for Eradication of P Aeruginosa Infection in Children With Cystic Fibrosis

Prospective Randomized Trial Comparing Oral Ciproxin Plus Inhaled Colistin With Tobramycin for Inhalation for Eradication of P Aeruginosa Infection in Children With Cystic Fibrosis.

Cystic Fibrosis

Drug: oral ciprofloxacin plus inhaled colistin;Drug: TOBI

Universitaire Ziekenhuizen Leuven

NULL

Completed

N/A

18 Years

Both

Phase 4

Belgium

NCT00006280
(ClinicalTrials.gov)

February 2000

11/9/2000

A Study of the Safety and Efficacy of Tobramycin for Inhalation in Young Children With Cystic Fibrosis

A Phase II Multicenter Randomized Trial of Tobramycin for Inhalation in Young Children With Cystic Fibrosis

Cystic Fibrosis

Drug: Tobramycin for Inhalation

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

National Center for Research Resources (NCRR)

Completed

6 Months

5 Years

Both

Phase 2

United States